Form 4: Core Scientific Director Acquires 20,448 Shares Through Restricted Stock Unit Grant

Core Scientific director Eric Stanton Weiss acquired 20,448 shares of common stock through a restricted stock unit grant.

Summary

• Eric Stanton Weiss, a director at Core Scientific, Inc., acquired 20,448 shares of common stock on January 27, 2025.
• The acquisition was through a grant of restricted stock units (RSUs).
• The RSUs will vest in full on January 27, 2026, provided Mr. Weiss continues to serve as a non-employee director.
• Following this transaction, Mr. Weiss beneficially owns 215,687 shares of Core Scientific common stock.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction of a director receiving equity compensation, which is generally viewed positively as it aligns interests with shareholders. There are no negative implications.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.

Future Outlook

The vesting of the RSUs is contingent on the director's continued service until January 27, 2026.

Industry Context

This is a standard transaction for directors of public companies, often used as part of their compensation package to align their interests with those of shareholders.

Comparison to Industry Standards

• Restricted stock unit grants are a common form of equity compensation for directors in publicly traded companies.
• The vesting period of one year is also typical for such grants.
• The size of the grant is not unusual for a director of a company of Core Scientific's size.

Stakeholder Impact

• The transaction increases the director's stake in the company, aligning his interests with those of shareholders.

Key Dates

Keywords

Core Scientific, Director, Stock Acquisition, Restricted Stock Units, RSU, Beneficial Ownership, Equity